ROCKVILLE, Md., Feb. 16, 2016 /PRNewswire/ -- TissueGene, Inc. (TGI), a regenerative medicine company using cell and gene therapy to develop novel regenerative drugs, is pleased to announce the appointment of Gurdyal Kalsi, M.D., to the role of Chief Medical Officer, SVP Clinical Development & Medical Affairs. Dr. Kalsi will oversee and direct the clinical development of TissueGene's novel injectable therapy for knee osteoarthritis (OA) called Invossa™. Invossa™ is a genetically-modified allogeneic cell therapy that will soon be entering Phase III clinical trials in the US.
Dr. Kalsi most recently served as Corporate Vice President for Clinical Development & Medical Affairs at Emergent BioSolutions Inc., where he was responsible for providing strategic and operational direction across Emergent's entire product pipeline.
"We are pleased to have Dr. Kalsi join the TissueGene Team. His vast experience will provide valuable assistance to the continued clinical development and commercialization of Invossa and help bring this novel therapy to market for the millions of patients suffering from knee OA," said Mr. Woosok Lee, President and CEO of TissueGene.
Dr. Kalsi brings significant expertise in clinical development across multiple therapeutic indications including osteoarthritis, rheumatoid arthritis as well as substantial clinical and surgical practice fluency combined with over 20 years of pharmaceutical/biotech industry experience in developing and commercializing products.
Prior to joining Emergent, Dr. Kalsi was heading Medical Affairs and Regulatory Affairs at MDS Pharma where he had responsibility for multiple therapeutic areas. Prior to this position, he held an executive leadership position with ICON Plc in clinical development and medical affairs. Dr. Kalsi began his pharmaceutical career at H Lundbeck A/S in Copenhagen, Denmark where he held a variety of positions with increasing responsibility in psychiatric disorders and neurological diseases.
Dr. Kalsi received his medical degrees in surgery and medicine from Glancy Medical School followed by post graduate training in public health medicine at St George's Hospital in London, and Pharmaceutical Medicine specialist training at Cardiff University, UK.
TissueGene Inc. is a regenerative medicine company based in Rockville, Maryland, specializing in cell and gene therapy. TissueGene has completed Phase 2 trials and has reached an agreement with the U.S. Food and Drug Administration regarding a Special Protocol Assessment (SPA) for a Phase 3 clinical trial for Invossa™, an allogeneic cell therapy for osteoarthritis of the knee. For additional information about TissueGene, Inc., please visit the Company's website at www.TissueGene.com.
SOURCE TissueGene, Inc.